Atossa Genetics

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform about breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

SEATTLE, June 14, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that Chief Executive Officer Steven Quay, M.D., Ph.D., and Chief Financial Officer Greg Weaver, will speak at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest on June 21, 2023 at 8:30 a.m., PT. The presentation will be available virtually and listeners can register here: https://m-vest.com/events/healthcare-06202023.

Atossa to Participate in Fireside Chat at Healthcare Virtual Conference Presented by Maxim Group LLC

Breast cancer is the leading cause of cancer death in American women, with around 280,000 women diagnosed annually, so anything that can predict the path of the disease and hopefully prevent its occurrence or its reoccurrence in patients would be very welcome indeed. One company looking to tackle the issue is Seattle-based Atossa Therapeutics Inc (NASDAQ:ATOS), a Nasdaq-listed clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer.

Atossa Therapeutics is looking for a step-change in breast cancer therapy

Atossa Therapeutics Inc (NASDAQ:ATOS), which is developing medicines aimed at oncology and breast cancer, revealed that the pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE study, evaluating Endoxifen versus exemestANe GosEreLIn, has now fully enrolled. The Seattle-based clinical-stage biopharma's EVANGELINE study is one of two ongoing Phase 2 trials investigating Atossa's proprietary (Z)-endoxifen as a neoadjuvant treatment, for women with estrogen receptor positive breast cancer.

Atossa finishes PK run-in cohort enrollment in breast cancer trial

SEATTLE, June 12, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully enrolled. EVANGELINE is a randomized non-inferiority trial of Atossa's patented Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, and exemestane plus goserelin as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer.

Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

American Lithium Corp

Precigen

Penny stocks can be rewarding. Look at Acadia Pharmaceuticals (NASDAQ: ACAD ), for example.

3 Penny Stocks That Could Skyrocket in the Next 12 Months

Atossa Therapeutics Inc (NASDAQ:ATOS) has found its new chief financial officer in veteran life sciences executive and longtime board member Greg Weaver.  Weaver brings more than 30 years of life science, financial and operations experience to Atossa, most recently serving as CFO BioIntelliSense, a privately held medtech company.

Atossa Therapeutics taps seasoned life sciences executive from its board to be CFO

SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces the appointment of Greg Weaver as the Company's new Chief Financial Officer (CFO). Mr. Weaver succeeds Kyle Guse.

Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer

Breast cancer drug clinical trial milestones and mergers and acquisitions (M&A) in 2023 should be catalysts for Atossa Therapeutics Inc (NASDAQ:ATOS)' stock, according to analysts at Ascendiant Capital Markets. “Atossa anticipates finishing or making significant milestones on its various clinical trials over the next year,” the analysts wrote in a note to clients published following the company's first-quarter results, which they noted were in line with expectations.

Atossa Therapeutics breast cancer drug trial milestones and CAR-T M&A likely catalysts, analysts say

Atossa Therapeutics Inc (NASDAQ:ATOS) reported financial results for its first quarter ended March 31, revealing progress in the development of its estrogen receptor (ER)-positive, HER2-negative breast cancer treatment (Z)-endoxifen. “I am proud of the progress we've made to date in 2023 and look forward to further accelerating our (Z)-endoxifen development programs over the coming months,” CEO Steven Quay said in a statement.

Atossa Therapeutics' 1Q results show ongoing breast cancer drug studies and robust cash on hand

SEATTLE, May 15, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces financial results for the fiscal quarter ended March 31, 2023, and provides an update on recent company developments.

Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

Atossa Therapeutics Inc (NASDAQ:ATOS) CEO Steven Quay has offered a set of recommendations to the United States Preventive Services Task Force (USPSTF) following the release of a draft report on breast cancer screening.  In the report, the USPSTF calls for mammograms to begin at 40 years of age, which returns the agency to its pre-2009 stance.

Atossa Therapeutics CEO Steven Quay weighs in on US agency's revised mammogram guidelines

SEATTLE , May 11, 2023 /PRNewswire/ -- Physician-Scientist Dr. Steven Quay, MD, PhD has provided a set of recommendations to the United States Preventive Services Task Force (USPSTF) following the publication of their draft report on breast cancer screening. The draft recommendations were made available for public comment on May 9, 2023 and can be found here: Breast Cancer: Screening.

Physician-Scientist Dr. Steven Quay Provides Recommendations to the United States Preventive Services Task Force on Breast Cancer Screening Policies and Practices

Atossa Therapeutics, Inc has announced that it will present a Trial in Progress poster for the Phase 2 clinical study of (Z)-endoxifen in premenopausal women with early stage ER+ / HER2- breast cancer (EVANGELINE) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be taking place from June 2-6, 2023, in Chicago. The clinical-stage biopharmaceutical company said the session, which will be presented by Dr Matthew Goetz of the Mayo Clinic, will take place on Sunday, June 4, 2023, from 8 AM to 11 AM Central Time.

Atossa Therapeutics to present insights from ongoing EVANGELINE clinical trial at ASCO Annual Meeting

SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces that a Trial in Progress poster for the Phase 2 clinical study of (Z)-endoxifen in premenopausal women with early stage ER+ / HER2- breast cancer will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago.

Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Cue Biopharma

Sana Biotechnology

Ardelyx

Bioline RX

Corvus Pharmaceuticals

Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ: AXSM ), for example.

7 High-Potential Penny Stocks in the Biotech Sector

SEATTLE, April 27, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in oncology with a current focus on breast cancer, today announces that Atossa's CEO, Steven Quay, M.D., Ph.D., will participate in a fireside chat and Q&A hosted by Tribe Public on Thursday, May 4, 2023 at 8:00 am pacific / 11:00 am eastern. Dr. Quay will provide an update on the clinical development of Atossa's proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, which is currently being investigated in three separate Phase 2 studies.

Atossa Therapeutics to Participate in Tribe Public's Webinar Event “Redefining Breast Cancer Prevention and Treatment”

As with all speculative investments, today's list of the best penny stocks under $1 should be approached with caution. Penny stocks are arguably one of the best ways to see outsized returns.

3 Best Penny Stocks Under $1 to Buy in April

Typically, penny stocks are pure market wages for hardened gamblers. In fact, penny stocks are always risky — especially some of the best biotech stocks under $1 – and should oftentimes be avoided.

The 3 Best Biotech Stocks Under $1 to Buy for April

SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced financial results for the fiscal quarter and fiscal year ended December 31, 2022 and provided an update on recent company developments.

Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update

SEATTLE and SAN FRANCISCO , March 21, 2023 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, and Quantum Leap Healthcare Collaborative™ today announce that Atossa's proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, will be evaluated in a new study arm of the ongoing I-SPY 2 clinical trial. The I-SPY 2 TRIAL evaluates neoadjuvant treatments for locally advanced breast cancer and is a collaborative effort among academic investigators from major cancer research centers across the United States, Quantum Leap Healthcare Collaborative, the U.S. Food and Drug Administration, and the Foundation for the National Institutes of Health (FNIH) Cancer Biomarkers Consortium.

Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial

SEATTLE and SAN FRANCISCO, March 21, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, and Quantum Leap Healthcare Collaborative™ today announce that Atossa's proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, will be evaluated in a new study arm of the ongoing I-SPY 2 clinical trial. The I-SPY 2 TRIAL evaluates neoadjuvant treatments for locally advanced breast cancer and is a collaborative effort among academic investigators from major cancer research centers across the United States, Quantum Leap Healthcare Collaborative, the U.S. Food and Drug Administration, and the Foundation for the National Institutes of Health (FNIH) Cancer Biomarkers Consortium. Approximately 20 patients will be treated with (Z)-endoxifen for up to 24 weeks prior to surgery.

Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial

SEATTLE, March 15, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced that the Company will present at the Sidoti Small-Cap Virtual Conference being held March 22-23, 2023. The presentation by Dr. Steven Quay, President and Chief Executive Officer and Kyle Guse, General Counsel and Chief Financial Officer, will take place on Thursday, March 23 at 1:00 pm eastern time.

Atossa to Present at the Sidoti Small-Cap Virtual Conference

SEATTLE, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in cancer, today announces that the first patient has been dosed in the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study. EVANGELINE is a randomized non-inferiority trial of Atossa's patented Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, and exemestane plus goserelin as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Participants will receive neoadjuvant treatment for up to six months, followed by surgery. The study is expected to enroll approximately 175 patients at up to 25 sites across the United States.

Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer

Amneal Pharmaceuticals

Selecta Biosciences

Troika Media Group

Penny stocks under $3 to watch this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 4 Stocks Under $3 To Watch This Week

SEATTLE, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in cancer, today announces that the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11,572,334) directed to (Z)-endoxifen encapsulated in an enteric capsule. This patent further reinforces Atossa's broad Intellectual Property portfolio related to (Z)-endoxifen. A short 'explainer' video about the new patent can be found here: Patent Update - Video Explainer.

News for Atossa Genetics Stock (ATOS)